Inactive Instrument

Metabolix, Inc. Stock Nasdaq

US5910188821

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

25-10-31	Yield10 Bioscience, Inc. Went Out of Business	CI
25-10-14	First Amended Joint Liquidation Plan Approved for Yield10 Bioscience, Inc.	CI

Analysts' recommendations: Metabolix, Inc.

24-02-08	Lake Street Downgrades Yield10 Bioscience to Hold From Buy, Cuts Price Target to $0.50 From $3	MT
23-08-17	HC Wainwright Adjusts Price Target on Yield10 Bioscience to $4 From $25, Keeps Buy Rating	MT
22-05-03	Univest Initiates Coverage of Yield10 Bioscience With Buy Rating, $5 Price Target	MT
22-05-03	Univest Securities Starts Yield10 Bioscience at Buy With $5 Price Target	MT
22-04-21	Lake Street Initiates Yield10 Bioscience at Buy with $12 Price Target	MT

More recommendations

Press Releases: Metabolix, Inc.

24-11-12	Yield10 Bioscience : Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals; Special Meeting Adjourned to Thursday, November 14, 2024 Form 8 K	PU
24-08-14	Yield10 Bioscience Announces Second Quarter 2024 Financial Results	AQ
24-07-17	Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets	AQ
24-06-17	Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina	AQ
24-06-12	Yield10 Bioscience : Certificate of Incorporation/Bylaws Form 8 K	PU

More press releases

Managers and Directors: Metabolix, Inc.

Manager	Title	Age	Since
Oliver Peoples CEO	Chief Executive Officer	68	2016-10-16
Charles Haaser DFI	Director of Finance/CFO	70	2014-11-02

Director	Title	Age	Since
Oliver Peoples BRD	Director/Board Member	68	2009-07-06
Robert van Nostrand CHM	Chairman	69	2011-11-07
Richard Hamilton BRD	Director/Board Member	63	2017-03-01

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.94%	+8.20%	-4.77%	+1.97%	46.2B
REVOLUTION MEDICINES, INC.	+5.79%	+18.18%	+421.86%	+619.81%	38.71B
IQVIA HOLDINGS INC.	+1.12%	+15.21%	+22.74%	-11.83%	31.9B
BEONE MEDICINES AG	+3.61%	+7.34%	+20.23%	+61.23%	31.12B
CELLTRION, INC.	+8.02%	+5.23%	+17.67%	+35.36%	23.77B
ASCENDIS PHARMA A/S	+1.13%	+14.24%	-	-	16.2B
MEDPACE HOLDINGS, INC.	+1.45%	+16.19%	+72.11%	+133.41%	15.05B
EUROFINS SCIENTIFIC SE	-1.13%	+9.05%	+12.03%	+18.95%	13.74B
IONIS PHARMACEUTICALS, INC.	-0.60%	+8.86%	+102.74%	+97.53%	13.42B
Average	+1.40%	+10.60%	+83.08%	+119.55%	25.57B
Weighted average by Cap.	+1.40%	+10.07%	+95.90%	+140.38%

See all sector performances

Yield10 Bioscience, Inc., formerly Metabolix, Inc., is an agricultural bioscience company. The Company is focused on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, the Company is advancing several yield traits it has developed in crops, such as Camelina, canola, soybean and corn. The Company concentrates on technologies that enables it to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter. The Company has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	229K 201K 185K 173K 326K 21.66M 333K 2.22M 860K 10.69M 860K 842K 37.09M	P/E 2022	-0.6x	P/E 2023	-0.13x
Enterprise Value	2.34M 2.05M 1.89M 1.76M 3.32M 221M 3.4M 22.71M 8.78M 109M 8.78M 8.59M 379M	EV / Sales 2022	14.6x	EV / Sales 2023	83x
Free-Float	-	Yield 2022 *	-	Yield 2023	-

25-10-31	Yield10 Bioscience, Inc. Went Out of Business	CI
25-10-14	First Amended Joint Liquidation Plan Approved for Yield10 Bioscience, Inc.	CI
25-08-20	First Amended Disclosure Statement Approved for Yield10 Bioscience, Inc.	CI
25-08-18	First Amended Joint Liquidation Plan and Disclosure Statement Filed by Yield10 Bioscience, Inc.	CI
25-07-10	Joint Liquidation Plan and Disclosure Statement Filed by Yield10 Bioscience, Inc.	CI
25-01-07	Motion for Asset Sale Approved for Yield10 Bioscience, Inc.	CI
24-12-09	Motion for Joint Administration Approved for Yield10 Bioscience, Inc.	CI
24-12-06	Yield10 Approves Wind Down of Operations and Corresponding Reduction in Workforce	CI
24-12-06	Yield10 Bioscience, Inc. Announces Board Changes	CI
24-12-06	Motion for Asset Sale Filed by Yield10 Bioscience, Inc.	CI
24-12-06	Yield10 Bioscience, Inc. Filed for Bankruptcy	CI
24-12-05	Motion for Joint Administration Filed by Yield10 Bioscience, Inc.	CI
24-11-11	Yield10 Bioscience, Inc. announced that it has received $3 million in funding	CI

	2022	2023
Net sales	450K 394K 363K 339K 639K 42.54M 653K 4.37M 1.69M 20.99M 1.69M 1.65M 72.85M	60K 52.52K 48.44K 45.27K 85.24K 5.67M 87.13K 583K 225K 2.8M 225K 220K 9.71M
Net income	-13.57M -11.87M -10.95M -10.23M -19.27M -1.28B -19.7M -132M -50.9M -633M -50.94M -49.83M -2.2B	-14.46M -12.65M -11.67M -10.91M -20.54M -1.37B -20.99M -140M -54.24M -674M -54.28M -53.09M -2.34B
Net Debt	-1.7M -1.49M -1.37M -1.28M -2.41M -160M -2.46M -16.48M -6.37M -79.14M -6.37M -6.23M -275M	2.11M 1.85M 1.7M 1.59M 3M 199M 3.06M 20.49M 7.92M 98.4M 7.92M 7.75M 342M

Metabolix, Inc. Stock Nasdaq

Stocks

US5910188821

Biotechnology & Medical Research

Valuation: Metabolix, Inc.

Latest news : Metabolix, Inc.

Analysts' recommendations: Metabolix, Inc.

Press Releases: Metabolix, Inc.

Managers and Directors: Metabolix, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile